Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Prostatic Neoplasms

Adenocarcinoma

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

70 Gy/CGE in 28 fractions of 2.5 Gy/CGE/fx

72.5 GY/CGE in 29 fractions of 2.5 Gy/CGE/fx

Low Risk Proton Radiation

Intermediate Risk Proton Radiation

Randal H Henderson, MD

The purpose of this trial is to give a shorter course (5 ½ weeks) of radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of radiation, without decreasing the chance of killing prostate cancer cells.

Low Risk - Total of 70 Gy/CGE over 28 treatments

Intermediate Risk - Total of 72.5 Gy/CGE over 29 treatments

Proton Therapy for Low and Intermediate Risk Prostate Cancer

A Phase II Study of Hypofractionated Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate

University of Florida

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

Randal Henderson, MD, MBA

Acute Grade 3 (NCI CTC v4.0) or Higher Treatment-related Toxicity Rate.

Disease Control

Overall Study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Proton Therapy for Low and Intermediate Risk Prostate Cancer	NCT00693238	Prostate Cancer	Low Risk Proton... Intermediate Ri...	18 Years -	University of Florida
Proton Therapy for Low and Intermediate Risk Prostate Cancer	NCT00693238	Prostate Cancer	Low Risk Proton... Intermediate Ri...	18 Years -	University of Florida

Spots Global Cancer Trial Database for intermediate risk proton radiation